Compensation for cures: Why we should pay a premium for participation in ‘challenge studies’
Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments - including risky experimental treatments such as phage therapy and vaccines - is an important part of improving our ability to treat infectio...
| Authors: | ; |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
Wiley-Blackwell
[2019]
|
| In: |
Bioethics
Year: 2019, Volume: 33, Issue: 7, Pages: 792-797 |
| IxTheo Classification: | NCH Medical ethics NCJ Ethics of science |
| Further subjects: | B
challenge studies
B antibiotic resistance B Consent B phage therapy B antibiotics |
| Online Access: |
Presumably Free Access Volltext (Verlag) Volltext (doi) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1727504119 | ||
| 003 | DE-627 | ||
| 005 | 20230426130552.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200820s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bioe.12596 |2 doi | |
| 035 | |a (DE-627)1727504119 | ||
| 035 | |a (DE-599)KXP1727504119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |e VerfasserIn |0 (DE-588)1209155710 |0 (DE-627)1696315158 |4 aut |a Anomaly, Jonathan | |
| 109 | |a Anomaly, Jonathan | ||
| 245 | 1 | 0 | |a Compensation for cures |b Why we should pay a premium for participation in ‘challenge studies’ |
| 264 | 1 | |c [2019] | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Antibiotic resistance is one of the most pressing public health problems humanity faces. Research into new classes of antibiotics and new kinds of treatments - including risky experimental treatments such as phage therapy and vaccines - is an important part of improving our ability to treat infectious diseases. In order to aid this research, we will argue that we should permit researchers to pay people any amount of money to compensate for the risks of participating in clinical trials, including ‘challenge studies’ that involve deliberately infecting patients. We think that standard worries about paying for participation in risky research are reducible to concerns that can be addressed with the right screening mechanisms. | ||
| 601 | |a Challenger | ||
| 650 | 4 | |a antibiotic resistance | |
| 650 | 4 | |a antibiotics | |
| 650 | 4 | |a challenge studies | |
| 650 | 4 | |a Consent | |
| 650 | 4 | |a phage therapy | |
| 652 | |a NCH:NCJ | ||
| 700 | 1 | |e VerfasserIn |0 (DE-588)1163621471 |0 (DE-627)102793496X |0 (DE-576)508091942 |4 aut |a Savulescu, Julian |d 1963- | |
| 773 | 0 | 8 | |i Enthalten in |t Bioethics |d Oxford [u.a.] : Wiley-Blackwell, 1987 |g 33(2019), 7, Seite 792-797 |h Online-Ressource |w (DE-627)271596708 |w (DE-600)1480658-7 |w (DE-576)078707986 |x 1467-8519 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2019 |g number:7 |g pages:792-797 |
| 856 | |u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bioe.12596 |x unpaywall |z Vermutlich kostenfreier Zugang |h publisher [open (via crossref license)] | ||
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1111/bioe.12596 |x Verlag |
| 856 | |u https://doi.org/10.1111/bioe.12596 |x doi |3 Volltext | ||
| 936 | u | w | |d 33 |j 2019 |e 7 |h 792-797 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 3741278343 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1727504119 | ||
| LOK | |0 005 20210929173537 | ||
| LOK | |0 008 200820||||||||||||||||ger||||||| | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixzo | ||
| LOK | |0 936ln |0 1550736558 |a NCH | ||
| LOK | |0 936ln |0 1550736582 |a NCJ | ||
| OAS | |a 1 | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||